December asinnovel Wuhan, 2019, coronavirus-infected acluster Hubeiof Province, acute respiratory China.1'5 pneumonia The illness, disease (NCIP), now has rapidly spread from Wuhan to other areas. As of January 31, 2020, a total of 9692 NCIP cases in China have been confirmed. Internationally, cases have been reported in 24 countriesand5continents.6On January3, 2020, the 2019 novel coronavirus (2019-nCoV) was identified in samples of bron¬ choalveolar lavagefluid from a patient in Wuhan and was con¬firmed as the cause of the NCIP.7 Full-genome sequencingand phylogenicanalysisindicated that 2019-nCoVis adistinctclade from the betacoronaviruses associated with human severe acute respiratory syndrome (SARS) and Middle East respira¬tory syndrome (MERS).7 The 2019-nCoV has features typical of the coronavirus family and was classified in the betacoro¬ navirus 2b lineage. The 2019-nCoV has close similarity to bat coronaviruses, and it has been postulated that batsare the pri¬ mary source. While the origin of the 2019-nCoV is still being investigated, current evidencesuggestsspread to humans occurred via transmission from wild animalsillegallysold in the Huanan Seafood Wholesale Market.8 Huang et al9first reported 41cases of NCIPin which most patients had a history of exposure to Huanan Seafood Whole¬ sale Market. Patients’ clinical manifestations included fever,nonproductive cough,dyspnea, myalgia,fatigue, normalor decreased leukocyte counts,and radiographicevidence of pneumonia. Organ dysfunction (eg, shock, acute respiratory distresssyndrome [ARDS],acute cardiacinjury,and acute kidney injury) and death can occur in severe cases.9 Subsequently, Chen et al8 reported findings from 99 cases of NCIP from the same hospital and the results suggested that the 2019-nCoV infection clustered within groups of humans in close contact, was more likely to affect older men with comorbidities, and could result in ARDS. However, the difference in clinical char¬ acteristics between severe and nonsevere cases was not reported. Case reports confirmed human-to-human transmission of NCIP.10,11 At present, there are no effective therapies or vaccines for NCIP. The objective of this case series was to describe the clinical characteristics of 138 hospitalized patients with NCIPand to comparesevere cases who received intensive care unit (ICU) care with nonsevere cases who did not receive ICU care.

Read More : Click Here